Skip to main content


On September 26, 2023, the FDA approved a new indication for bosutinib (Bosulif; Pfizer), a tyrosine kinase inhibitor, for the treatment of chronic-phase, Philadelphia chromosome–positive chronic myelogenous leukemia in pediatric patients aged ≥1 years who are newly diagnosed or who are intolerant of or whose disease is resistant to previous therapy. A new capsule dosage form was also FDA approved, in 50-mg and 100-mg strengths; bosutinib was previously available only in 100-mg, 400-mg, and 500-mg tablet forms. The FDA granted this approval priority review and an orphan drug designation. Read More ›

In a session during the 2023 National Comprehensive Cancer Network (NCCN) Annual Conference, Deborah M. Stephens, DO, provided important updates to treatment recommendations for patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), and identified key factors for selecting frontline and subsequent therapies, including IGHV gene status, 17p deletion/TP53 mutation status, age, patient comorbidities, and resistance mutations. Read More ›

On January 19, 2023, the FDA approved zanubrutinib (Brukinsa; BeiGene USA), a Bruton tyrosine kinase (BTK) inhibitor, for the treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The FDA granted zanubrutinib an orphan drug designation for this indication. Read More ›

A head-to-head phase 3 clinical trial in patients with relapsed or refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) has found that zanubrutinib (Brukinsa), a next-generation Bruton tyrosine kinase (BTK) inhibitor, was more effective at preventing disease progression and is better tolerated than ibrutinib (Imbruvica), a first-generation BTK inhibitor that is the current standard of care for this population of patients. Read More ›

On December 1, 2022, the FDA approved olutasidenib (Rezlidhia; Forma Therapeutics) capsules, an oral IDH1 inhibitor, for adults with relapsed or refractory acute myeloid leukemia (AML) and a susceptible IDH1 mutation, as detected by an FDA-approved test. Read More ›

The treatment of acute myeloid leukemia (AML) has entered a new era, with the use of more potent therapies, such as targeted agents and venetoclax (Venclexta). Read More ›

On October 16, 2020, the FDA granted full approval to venetoclax (Venclexta; AbbVie and Genentech) in combination with azacitidine, decitabine, or low-dose cytarabine for newly diagnosed acute myeloid leukemia (AML) in adults aged ≥75 years or who have comorbidities precluding intensive induction chemotherapy. Read More ›

Selpercatinib Shows Durable Responses in Patients with Thyroid Cancer and RET Mutation
Venclexta plus Azacitidine Improves Overall Survival in Patients with AML
Advances in New Therapies Attributed to Reductions in Lung Cancer Mortality
Read More ›

A total of 80% of patients with relapsed or refractory indolent non-Hodgkin lymphoma (NHL) achieved a complete response (CR) to axicabtagene ciloleucel (Yescarta), and those responses have proved durable, according to the interim results of the phase 2 ZUMA-5 study, said Caron A. Jacobson, MD, Medical Director, Immune Effector Cell Therapy Program, Dana-Farber Cancer Institute, Boston, MA, at the ASCO 2020 virtual annual meeting. Read More ›

According to long-term follow-up data presented at the ASCO 2020 virtual annual meeting, anti-CD19 chimeric antigen receptor (CAR) T-cell therapy has demonstrated ongoing durable remissions lasting up to 113 months for follicular lymphoma, 99 months for chronic lymphocytic leukemia (CLL), and 97 months for diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL). What’s more, long-term adverse events were rare, with the exception of prolonged B-cell depletion and hypogammaglobulinemia. Read More ›

Page 1 of 4